Cell Therapy News Volume 27.07 | Apr 27 2026

    0
    26






    2026-04-27 | CTN 27.07


    Cell Therapy News by STEMCELL Technologies
    Vol. 27.06 – 27 April, 2026
    TOP STORY

    Therapeutic Targeting of BCL-2 during CAR T Cell Production Augments Potency through Non-Apoptotic Adaptive Changes

    Researchers revealed that venetoclax treatment during ex vivo expansion of CART cells, prepared from T cells from healthy donors or chemotherapeutically pretreated patients, potently augments antitumor efficacy in a BCL-2-dependent manner.
    [Signal Transduction and Targeted Therapy]

    Full Article
    PUBLICATIONSListed by the impact factor of the journal

    CAR-Neutrophils Produced In Vivo to Treat Glioma

    Scientists developed a neutrophil-specific modified RNA translation platform, termed NeuSMRT, that enables the expression of CARs in primary neutrophils. In a syngeneic glioma model, CAR-neutrophils produced in vivo significantly inhibited tumor growth and prolonged survival.
    [Nature Biomedical Engineering]

    Abstract

    Harnessing the CD2 Axis to Broaden and Enhance the Efficacy of CAR T-Cell Therapies

    Investigators hypothesized that targeting CD2, a pan–T-cell antigen, with anti-CD2 CAR T cells engineered to lack CD2 expression would improve manufacturability and preclinical efficacy.
    [Blood]

    Abstract

    Modeling Chimeric Antigen Receptor Response at the Single-Cell Level with Conditional Optimal Transport

    The authors introduced an optimal transport-based framework designed to predict responses to CAR expression at the single-cell level, including variants that have not been experimentally tested.
    [Cell Systems]

    Full Article

    Granzyme B-Based CAR-T Cells Targeting Membrane-Bound HSP70 Suppress Solid Tumor Growth and Metastasis

    Scientists generated CAR T cells based on natural ligand granzyme B (GrB-CAR T) targeting membrane-bound HSP70. GrB-CAR T cells exhibit potent cytotoxicity against a broad spectrum of cancer cell lines and stem-like cancer cells in vitro.
    [Oncogene]

    Abstract

    Perfusion Microbioreactor for CAR-Treg Manufacturing

    Researchers developed the KCL-Microbioreactor, a closed microbioreactor platform based on microfluidic principles. They demonstrated the platform’s utility by generating functional CAR-regulatory T cells targeting HLA-A2.
    [IScience]

    Full Article | Graphical Abstract
    REVIEWS

    CAR-X Cell Engineering

    The authors discuss different CAR-engineered immune cells for therapeutic applications by highlighting how unique immune attributes, along with cell-specific manufacturing strategies and CAR designs, address challenges faced by conventional CAR-T cell therapy.
    [Nature Reviews Bioengineering]

    Abstract

    Optimizing In Vivo CAR T-Cell Engineering for Cancer Immunotherapy

    Scientists focus on current in vivo CAR T delivery strategies, including viral vectors and nonviral systems, with a focus on how these platforms are engineered to achieve efficient, specific, and safe CAR transgene transfer.
    [Cancer Research]

    Abstract

    Application of CAR-T Therapy in Solid Tumors: Current Opportunities and Challenges

    Investigators summarize advancements in CAR-T therapy for solid tumors, including lung, pancreatic, and breast cancer. They discuss major barriers to CAR-T application in solid tumors, including antigen heterogeneity, the lack of specific targets, CAR-T cell exhaustion, and physical barriers within tumor tissues.
    [Cancer Gene Therapy]

    Abstract
    INDUSTRY AND POLICY NEWS

    Grants for Research on Immune Cells, Vegan Cheese, and PFAS Detection

    Dr. Heyang Zhang is developing a safer and more scalable way to reprogramme T cells for CAR T-cell therapy, with the aim of making these treatments more widely accessible.
    [Leiden University]

    Press Release

    The Center for Cancer and Blood Disorders Receives Authorization to Administer FDA-Approved CAR T-Cell Therapy; Begins Treating First Community Oncology Patient in Maryland-Area Clinic

    The Center for Cancer and Blood Disorders (CCBD) announced it has launched a new program to deliver CAR-T cell therapy to patients in the Maryland area.
    [CCBD]

    Press Release
    FEATURED EVENT

    Mammary Gland Biology

    May 31-June 5, 2026
    Barga, Italy

    > See All Events

    JOB OPPORTUNITIES

    Research Group Leader – Cardiopulmonary Molecular Biology

    Medical University of Vienna – Vienna, Austria

    Postdoctoral Fellow- Genome Editing and Gene Therapy

    The Icahn School of Medicine at Mount Sinai – New York City, New York, United States

    Postdoctoral Fellow – T Cell Signaling and CAR-T Immunotherapy

    University of Montreal – Montreal, Quebec, Canada

    Research Scientist Positions – Cancer and Stem Cell Biology

    University of Virginia – Charlottesville, Virginia, United States

    Postdoctoral/Research Scientist – CAR-T Therapeutics

    Stanford University – Stanford, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2